Chemomab Therapeutics (CMMB) Total Liabilities (2017 - 2026)

Chemomab Therapeutics (CMMB) has reported Total Liabilities for 10 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 8.6% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (up 8.6% YoY), and the FY2025 full-year result was $1.5 million, down 56.87% from the prior year.
• Total Liabilities grew to $1.6 million in Q2 2026 per CMMB's latest filing, from $1.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $7.1 million in Q1 2023 and bottomed at $1.1 million in Q1 2026.
• Historically, Total Liabilities has averaged $4.0 million across 5 years, with a median of $4.6 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 190.2% in 2022, then slumped 75.17% in 2025.
• Over 5 years, Total Liabilities stood at $6.8 million in 2022, then fell by 24.65% to $5.2 million in 2023, then slumped by 33.51% to $3.4 million in 2024, then tumbled by 56.87% to $1.5 million in 2025, then advanced by 5.07% to $1.6 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $1.6 million, $1.1 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.